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Necrosis can induce profound inflammation or be
clinically silent. However, themechanismsunderlying
such tissue specificity are unknown. Interleukin-1a
(IL-1a) is a key danger signal released upon necrosis
that exerts effects on both innate and adaptive
immunity and is considered to be constitutively
active. In contrast, we have shown that necrosis-
induced IL-1a activity is tightly controlled in a cell
type-specific manner. Most cell types examined ex-
pressed a cytosolic IL-1 receptor 2 (IL-1R2) whose
binding to pro-IL-1a inhibited its cytokine activity. In
cell types exhibiting a silent necrotic phenotype,
IL-1R2 remained associated with pro-IL-1a. Cell
types possessing inflammatory necrotic phenotypes
either lacked IL-1R2 or had activated caspase-1
before necrosis, which degraded and dissociated
IL-1R2 from pro-IL-1a. Full IL-1a activity required
cleavage by calpain after necrosis, which increased
its affinity for IL-1 receptor 1. Thus, we report a cell
type-dependent process that fundamentally governs
IL-1a activity postnecrosis and the mechanism
allowing conditional release of this blockade.
INTRODUCTION
Understandingwhy the immune system responds to necrosis and
how this is controlled is critical in unraveling multiple human
diseases. The ‘‘danger’’ model proposes that immunity responds
to nonphysiological cell death, damage, or stress (Matzinger,
1994). Accordingly, necrotic death releases damage-associated
molecular patterns (DAMPs), which are sensed as danger and
act as universal signals to activate immunity (Chen and Nun˜ez,
2010; Kono and Rock, 2008; Rock et al., 2010). DAMPs are
retained in healthy cells and during apoptosis (Basu et al., 2000;
Cohenetal., 2010;Scaffidi etal., 2002),whereasnecrosis releases
them into the extracellular milieu. Interleukin-1a (IL-1a) is an
important DAMP that activates immunity postnecrosis (Chen
et al., 2007; Clarke et al., 2010; Cohen et al., 2010; Eigenbrod
et al., 2008;Konoet al., 2010;Raoet al., 2007), drivingpathologies
as diverse as tumorigenesis (Sakurai et al., 2008), atherosclerosis(Clarke et al., 2010; Kamari et al., 2007), graft rejection (Rao et al.,
2007, 2008), toxic liver insults (Chen et al., 2007), and ischemia-
reperfusion injury (Cohen et al., 2010; Luheshi et al., 2011).
The prototypic IL-1 family is ancient, with homologs identified
back to echinoderms (Beck and Habicht, 1986). IL-1a, one of the
principal ligands, is expressed by most lineages as a signal
peptide-less protein, is not readily secreted (Dinarello, 2009),
and is actively retained during apoptosis (Cohen et al., 2010).
Once released into the extracellular milieu, IL-1a ligation of the
type 1 IL-1 receptor (IL-1R1) leads to multiple proinflammatory
effects (Dinarello, 2009), including cytokine secretion, neutrophil
recruitment, and upregulation of major histocompatibility
complex (MHC) and costimulatory molecules on antigen-
presenting cells. IL-1a also has powerful effects on adaptive
immunity by enhancing expansion and survival of T cells, differ-
entiation of T helper 17 (Th17) cells, and effector T cell prolifera-
tion in the presence of regulatory T cells (Sims and Smith, 2010).
These potent effects mean that activity is tightly controlled at
multiple levels. Mice deficient in IL-1a or IL-1b exhibit no
phenotype. However, mice lacking the IL-1 receptor antagonist
(IL-1RA) have small litters and retarded growth and develop
spontaneous arthritis-like polyarthropathy, arteritis, and cancer
(Dinarello, 2009). Indeed, increased IL-1 activity is a hallmark
of many chronic inflammatory conditions, including rheumatoid
arthritis, gout, diabetes, atherosclerosis, and psoriasis (Dinar-
ello, 1996, 2009; Duewell et al., 2010; Rajama¨ki et al., 2010).
IL-1 family members are synthesized as inactive precursors
unable to bind their receptor, providing an initial level of control.
IL-1band IL-18areactivatedbycaspase-1,which requires inflam-
masome formation. In contrast, IL-33 processing by caspase-3
or caspase-1 results in inactivation (Cayrol andGirard, 2009; Lu¨thi
et al., 2009). Pro-IL-1a (p33) is processed tomature IL-1a (p17) by
calpain (Kobayashi et al., 1990), but the biological consequences
of cleavage are unknown given that p33 is reported to be fully
active. This finding is credited to two papers, but one only
discusses p33 activity (March et al., 1985), whereas activity within
the second study may be compromised by p33 degradation
(Mosley et al., 1987). Interestingly, calpain is activated upon loss
of plasma membrane integrity (Wang, 2000), suggesting that
calpain cleavageof IL-1a could be a control point for activity post-
necrosis. Although a recent study reports increased IL-1a activity
after granzyme B cleavage (Afonina et al., 2011), differential
efficacy of p33 and p17 IL-1a is still controversial (Gross et al.,
2012), and no mechanism to explain this has been reported.Immunity 38, 285–295, February 21, 2013 ª2013 Elsevier Inc. 285
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Figure 1. Necrosis-Induced Sterile Inflam-
mation Is Cell Type Specific
(A) IL-6 concentrations in conditioned media of
macrophages (Macs), Jurkat cells, or VSMCs
incubated with lysates from their respective
necrotic cells or with IL-1a.
(B and C) Immunoblots of IL-1a content and pro-
cessing in whole cell (WC) or necrotic lysates (NL)
(B) or in necrotic cell lysates pretreated with
protease inhibitors as indicated (C).
(D and E) IL-6 and MCP-1 concentrations in
conditioned media of VSMCs incubated with
necrotic VSMC lysates made in the presence of
protease inhibitors (D), or with IL-1a alone, or with
calpeptin or EGTA (E).
Data represent mean ± SD; *p % 0.007 versus
control, n = 3; **p% 0.03 (MCP-1), p% 0.002 (IL-
6), nR 4. NS, not significant. See also Figure S1.
Immunity
IL-1R2 Controls IL-1a Activity PostnecrosisWe report that necrosis-induced IL-1a-dependent responses
are highly cell type dependent and correlate with calpain
cleavage of IL-1a during necrosis. Contrary to current under-
standing, p33 requires calpain processing for full biological
activity, which increases its affinity for IL-1R1. Cell type depen-
dency occurs due to expression of an intracellular form of IL-
1R2 that binds IL-1a, preventing calpain cleavage and cytokine
activity. After inflammasome activation, caspase-1 specifically
cleaves IL-1R2, which abrogates IL-1a binding, allows calpain
cleavage, and completely restores IL-1a-dependent responses.
Regulated secretion of IL-1a also requires IL-1R2 cleavage.
Thus, we report an important cell type-dependent mechanism
that fundamentally governs IL-1a activity postnecrosis and the
mechanism allowing conditional release of this blockade.
RESULTS
Necrosis-Induced Sterile Inflammation Is Cell Type
Specific and Correlates with Calpain Cleavage
of pro-IL-1a
We have recently shown that IL-1a released during vascular
smooth muscle cell (VSMC) necrosis is a powerful DAMP that
induces local vessel inflammation (Clarke et al., 2010). To deter-
mine which other cell types could drive IL-1a-dependent sterile286 Immunity 38, 285–295, February 21, 2013 ª2013 Elsevier Inc.inflammation, we analyzed IL-6 release
from VSMCs, Jurkat cells, and primary
macrophages treated with lysates from
these cell types undergoing necrosis.
Only necrotic VSMCs induced significant
IL-6 release from viable VSMCs, previ-
ously shown to be IL-1a dependent
(Clarke et al., 2010), and only VSMCs re-
sponded to IL-1a (Figure 1A). Little IL-1a
activity was found in membrane fractions
of necrotic macrophages or Jurkat cells
(Figure S1A available online) or in lysates
from cells undergoing hypoxia-induced
necrosis (Figure S1B). Although compa-
rable amounts of IL-1a were found in all
three cell types, only VSMCs processedp33 to p17 IL-1a (Figure 1B). Calpain cleaves p33 to p17
(Kobayashi et al., 1990); however, the relevance of cleavage
to IL-1a activity is unknown. Several reports indicate that pro-
cessing is not required for secretion (Brough et al., 2003;
Prudovsky et al., 2003), and cytokine activity is supposedly inde-
pendent of cleavage (March et al., 1985; Mosley et al., 1987).
VSMCs rapidly cleaved p33 to p17 during necrosis, which
was prevented by the calpain inhibitors calpeptin and EGTA
but not the proteasomal inhibitor lactacystin (Figure 1C).
Necrotic VSMC lysates prepared with calpain inhibition
produced significantly reduced responses (Figure 1D), whereas
calpeptin or EGTA treatment did not inhibit cytokine production
in response to IL-1a (Figure 1E). However, prolonged incubation
at 37C in the presence of calpeptin resulted in some processing
of p33 to p17 (Figure S1C), which could contribute to the
apparent IL-1a activity seen with calpeptin-treated VSMCs
(Figure 1D). Nevertheless, taken together this suggests that,
contrary to the accepted literature, p33 is not fully active until
cleaved.
Calpain-Cleaved p33 and Recombinant p17 Are More
Active than p33 IL-1a
To directly compare p17 and p33 activity, we purified HIS-
tagged recombinant proteins. Although we could express and
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Figure 2. Calpain-Cleaved p33 and Recom-
binant p17 Is More Active than p33 IL-1a
(A) Cytokine concentrations in conditioned media
of VSMCs treated with p33 or calpain-cleaved
p33, ± IL-1a neutralizing antibody (a pAb).
(B) VSMCs were also treated with calpain sham
reactions (no p33) or commercial recombinant
p17 IL-1a (cr17) ± calpain sham.
(C) IL-2 concentration in conditioned media of
murine EL4 cells treated with p33 ± calpain.
(D) Immunoblot of in vitro cleavage of p33 by
calpain.
(E) Coomassie stain of purified soluble p17- and
p33-GST fusion proteins.
(F and G) IL-2 (F) or IL-6 (G) concentrations in
conditioned media of EL4 or VSMCs, respectively,
treated with 1 nM p17- or p33-GST ± a pAb.
(H) IL-2 concentrations in conditioned media of
EL4 cells incubated with p33-GST ± calpain, and ±
a pAb.
(I) GR1+ cells recruited intraperitoneally in wild-
type or Il1r1/ mice injected with saline or
29 fmol/g p17 or p33.
Data represent mean ± SD or mean ± SEM (I);
*p% 0.0003, n = 4 (A), n = 3 (B, C) protein prepa-
rations and cleavage reactions; **p% 0.007, n = 4.
NS, not significant.
Immunity
IL-1R2 Controls IL-1a Activity Postnecrosispurify p17 in E. coli, p33 was very insoluble and prone to
aggregation (not shown)—a finding reported by others
(Tokunaga et al., 2010). After denaturation in urea, p33 could
be purified and renatured to a soluble protein after sequential
dialysis, but this made comparison between p17 and p33
impossible because of the inability to control for refolding effi-
ciency between different proteins. To circumvent this, we
cleaved p33 in vitro with calpain, which increased cytokine
release compared to uncleaved p33 (Figure 2A). Importantly,
a neutralizing antibody to IL-1a reduced responses to control
(Figure 2A), whereas a ‘‘calpain sham’’ reaction without p33
neither promoted nor inhibited cytokine release (Figure 2B),Immunity 38, 285–295,indicating that the increased activity is
due to processing of p33 to p17. These
data were also reproduced cross-species
with the classic IL-1-sensitive murine
cell line EL4 (Figure 2C), suggesting
a conserved requirement for calpain
processing of IL-1a. Although calpain
cleavage of IL-1a increased activity,
these differences represent an underesti-
mate because of the nonstoichiometric
conversion of p33 to p17 during in vitro
cleavage (Figure 2D).
By fusing IL-1a to GST, we purified
small amounts of p17 and p33 as soluble
proteins (145 mg/l) (Figure 2E). Compar-
ison at equal molarities demonstrated
significant increases in IL-2 release from
EL4 cells (Figure 2F) and IL-6 release
from VSMCs for p17 compared to p33
(Figure 2G). IL-1a neutralization reducedresponses to control indicating IL-1a-dependent stimulation,
excluding effects from copurified bacterial PAMPs (Figures 2F
and 2G). To eliminate whether GST-p33 was ‘‘functionally
dead’’ as a result of a purification artifact or intrinsic instability,
we cleaved it with calpain or incubated it at 37C for 16 hr,
respectively. Cleavage of GST-p33 significantly restored
activity (Figure 2H), whereas incubation did not result in protein
degradation (not shown), again supporting an inherent lower
activity of p33. Lastly, injection of p17 into the peritoneum
resulted in significantly increased neutrophil recruitment
compared to injection of p33 in wild-type mice, a result that
was not seen in Il1r1/ mice (Figure 2I).February 21, 2013 ª2013 Elsevier Inc. 287
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Figure 3. p33 IL-1a Shows Minimal Activity
at Physiological Concentrations because
of Lower Receptor Affinity
(A and B) Concentration-response curves to p17
and p33, minus control, in VSMCs (50 pM to 8 nM)
(A) or EL4 cells (5 pM to 8 nM) (B).
(C and D) IL-2 concentrations in conditionedmedia
from EL4 cells treated with p17 or p33 at 4 nM (C),
and 0.1 nM p17 or 4 nM p33 (D), with increasing
concentrations of IL-1RA.
Data represent mean ± SD; *p % 0.03, n = 3 (A),
n R 4 (B); for difference in IC50 p < 0.0001 (C),
p = 0.52 (D), n = 3. See also Figure S2.
Immunity
IL-1R2 Controls IL-1a Activity Postnecrosisp33 IL-1a Shows Minimal Activity and Behaves as
a Partial Agonist due to a Lower Receptor Affinity
To understand why p33 is less active than p17, we generated
cytokine concentration-response curves. VSMCs responded to
p17 at 50 pM and saturated at 2 nM (Figure 3A). In contrast,
p33 generated responses only at supraphysiological amounts
and failed to saturate (Figure 3A). At physiological concentra-
tions of 1 nM, p17was50 timesmore active than p33. EL4 cells
are very sensitive to IL-1a, with responses detectable with fM
amounts. p17 activity was detectable at 5 pM and rapidly satu-
rated at 0.5 nM (Figure 3B). However, p33 gave a linear concen-
tration response, such that 65% of the maximal response was
obtained at 8 nM but did not reach saturation (Figure 3B). At
1 nM p17 was10 timesmore active than p33. To exclude steric
hindrance of fused GST only on p33, we specifically cleaved off
GST. Comparison of p33 with or without GST revealed identical
efficacies at a range of concentrations (Figure S2). Together, this
suggests that p33 can bind IL-1R1 at higher concentrations and
thus acts as a partial agonist.
To investigate whether p33 binds IL-1R1 but fails to induce
downstream signaling, we conducted competition experiments
with a fixed concentration of p17 (1 nM) and increasing concen-
trations of p33 (up to 8 nM). However, even 8 nM p33 failed to
inhibit cytokine responses (data not shown), suggesting
a stronger affinity of p17 for the receptor. IL-1RA binds IL-1R1
but does not induce signaling (Dinarello, 2009). Therefore the
difference in concentration of IL-1RA required to inhibit 50%
of the cytokine response induced by p17 or p33 (the IC50)
directly relates to the difference in affinity of the two ligands
for IL-1R1. Responses to 4 nM p33 were completely inhibited
by 100 ng/ml IL-1RA (IC50 of 13.7 ± 3.8 ng/ml) (Figure 3C). In
contrast, 1,600 ng/ml IL-1RA failed to inhibit responses to
4 nMp17, but 50% inhibition occurred at 633.3 ± 16.7 ng/ml (Fig-
ure 3C). This indicates that p33 has an affinity for IL-1R1 46.3
times lower than does p17 (p < 0.0001). To exclude p17
responses from another receptor insensitive to IL-1RA blockade,
we repeated with 0.1 nM p17. Under these conditions 100 ng/ml288 Immunity 38, 285–295, February 21, 2013 ª2013 Elsevier Inc.IL-1RA completely inhibited cytokine
release and gave an IC50 of 10.3 ±
2.9 ng/ml (Figure 3D). Thus, a 40-fold
difference in concentration gave near
superimposable curves (p = 0.52), corre-
lating well with the value above. Together
these data show that, in contrast to
previous reports, IL-1a is not fully activeuntil processed by calpain and that cell types unable to cleave
IL-1a induce much smaller IL-1a-dependent responses after
necrosis.
An Intracellular Form of IL-1R2 Protects p33 IL-1a
from Calpain Processing
We hypothesized that cell type-specific cleavage of IL-1a could
occur through modification of enzyme or substrate, excess of
a calpain inhibitor, or a binding partner that protects IL-1a from
processing. Jurkat and macrophage necrotic lysates incubated
at 37C for extended periods still showed no processing of
endogenous p33 (Figure 4A), whereas recombinant His-p33
spiked into Jurkat lysates also remained uncleaved (Figure 4A),
excluding a modification to the cell-derived cytokine. Similar
results were also found with primary T lymphocytes (Fig-
ure S3A). An excess of calpain inhibitor was excluded, because
high calpain activity was found in all necrotic cell types (Fig-
ure S3B). Addition of purified calpain to Jurkat necrotic lysates
also failed to cleave p33 (Figure 4B), whereas analysis of spec-
trin, an alternative calpain substrate, revealed calpain-depen-
dent processing in both Jurkat and VSMCs necrotic lysates
(Figure 4C).
Protection of recombinant p33 by Jurkat necrotic lysates
suggested that an excess of a binding partner must be present,
and therefore that it could be transferred. Indeed, necrotic
lysates made from mixed Jurkat and VSMCs displayed no
p33 cleavage (Figure 4D). Known binding partners of IL-1a
include the type 1 and 2 IL-1 receptors; therefore we treated
Jurkat necrotic lysates with a large excess of IL-1RA, which
resulted in calpain-specific cleavage of p33 (Figure S3C). The
only known receptors for IL-1RA are IL-1R1 and IL-1R2, sug-
gesting that IL-1a may be bound to an intracellular IL-1R.
RT-PCR revealed that VSMCs express only IL-1R1, whereas
Jurkat cells (Figure 4E) and macrophages (data not shown)
express IL-1R2. Immunoblots confirmed IL-1R2 expression in
Jurkat cells (Figure 4F), macrophages, and T cells (Figure S3D),
whereas addition of recombinant IL-1R2 to a cell-free cleavage
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Figure 4. An Intracellular Form of IL-1R2 Protects IL-1a from Calpain Processing
(A and B) Immunoblot for endogenous IL-1a processing in necrotic lysates of primary macrophages (Macs) and Jurkat cells (A), for exogenous His-p33 in necrotic
Jurkat lysates (A), or for Jurkat necrotic lysates treated with increasing amounts of purified calpain (B).
(C and D) Immunoblot of whole cell (WC) and necrotic (NL) Jurkat and VSMC lysates for a-spectrin (C) or IL-1a after mixing of lysates from both cell types (D).
(E and F) RT-PCR (E) or immunoblot (F) for IL-1 receptors in VSMCs and Jurkat cells.
(G and H) Immunoblot for IL-1a cleavage in a cell-free system with purified calpain (G) and in necrotic VSMC lysates (H), ± 250 ng IL-1R2.
(I and J) Coimmunoprecipitation of IL-1R2 with p33-GST (I) and p33 with IL-1R2-HIS (J) in transfected HEK cell lysates.
See also Figure S3.
Immunity
IL-1R2 Controls IL-1a Activity Postnecrosisreaction (Figure 4G) or necrotic VSMC lysates (Figure 4H) pre-
vented calpain-dependent p33 processing in a dose-depen-
dent manner (Figure S3E). IL-1R2 also antagonized p33 in
a dose-dependent manner (Figure S3F). Importantly, IL-1R2
coimmunoprecipitated with p33-GST and p33 with IL-1R2-HIS (Figures 4I and 4J), whereas a proximity ligation assay
demonstrated association of endogenous proteins in situ (Fig-
ure S3G), supporting a direct interaction. Finally, IL-1R2 also
protected IL-1a from cleavage by the inflammatory proteases
granzyme B, chymase, and elastase (Figure S3H).Immunity 38, 285–295, February 21, 2013 ª2013 Elsevier Inc. 289
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Figure 5. Silencing of IL-1R2 Enables IL-1a
Processing and Restores Necrotic Cell-
Induced Inflammation
(A–C) siRNA-mediated silencing reduces IL-1R2
mRNA (A) and protein in whole cell (WC) and
necrotic lysates (NL) (B), which leads to calpain-
dependent IL-1a cleavage upon necrosis (C) that
is inhibited with calpeptin (+C).
(D and E) IL-2 concentrations in conditionedmedia
of EL4 cells incubated with necrotic lysates from
HeLa cells treated with siRNA to IL-1R2 or
scrambled, either alone (D) or with IL-1b treatment
(E), ± a pAb. Data represent mean ± SD;
*p = 0.0007, n = 3 independent silencings and
treatments. NS, not significant.
(F) GR1+ cells recruited intraperitoneally in wild-
type or Il1r1/ mice injected with saline or 8.3 3
105 control or IL-1R2-silenced necrotic HeLa cells.
Data represent mean ± SEM; **p% 0.006, nR 4.
NS, not significant.
(G) Immunoblot for IL-1R2 and IL-1a in necrotic
lysates of empty vector or soluble IL-1R2-trans-
fected VSMCs.
See also Figure S4.
Immunity
IL-1R2 Controls IL-1a Activity PostnecrosisIL-1R2 Silencing Enables Calpain Cleavage of p33 IL-1a
and Restores Inflammatory Response to Necrotic Cells
Low transfection efficiency and suspension growth made Jurkat
cells unsuitable for siRNA silencing. Therefore, necrotic HeLa
cells were tested for p33 cleavage (Figure S4A), calpain activity
(data not shown), and IL-1R2 expression (Figures 5A and 5B),
which indicated that they responded similarly. siRNA to IL-1R2
reduced both IL-1R2 mRNA (Figure 5A) and protein (Figure 5B),
which was not seen with scrambled control. After IL-1R2
silencing, necrotic HeLa lysates displayed calpain-dependent
processing of p33 to p17 (Figure 5C) and restoration of IL-
1a-dependent responses (Figure 5D), whereas scrambled
control cells did not. Because IL-1R2 functions as a decoy290 Immunity 38, 285–295, February 21, 2013 ª2013 Elsevier Inc.receptor that limits bioavailability of IL-1
(Colotta et al., 1993), we examined
whether IL-1R2 silencing had reversed
‘‘general’’ IL-1 antagonism within
necrotic lysates. By neutralizing all IL-1a
activity within necrotic lysates, we com-
pared responsiveness to IL-1b with or
without scrambled or IL-1R2-silenced
necrotic lysates present (Figure 5E). This
revealed no significant difference in
IL-2 production, implying that IL-1R2
silencing hadn’t simply reduced general
IL-1 antagonism. Sterile peritonitis
induced with scrambled control necrotic
lysates recruited equal numbers of
neutrophils in wild-type and Il1r1/
mice, therefore representing IL-1-inde-
pendent responses (Figure 5F). However,
IL-1R2-silenced necrotic lysates re-
cruited 3-fold more cells, which was IL-1
dependent because of loss of response
in Il1r1/ mice (Figure 5F). Because
previously described forms of IL-1R2 retain a signal peptide
(Liu et al., 1996), they would be expected to be in the exocytic
pathway. Therefore we determined whether cell surface-shed
IL-1R2 (Orlando et al., 1997) protects IL-1a by inhibiting metallo-
proteases with BB-94; p33, however, remained uncleaved (Fig-
ure S4B). Furthermore, immunofluorescence revealed a large
amount of IL-1R2 to be intracellular (Figure S4C) in multiple cell
types (Figure S4D) and endogenous p33 and IL-1R2 to be highly
colocalized (Figure S4E) throughout the cytoplasm (Figure S4F).
In addition, subcellular fractionation (Figure S4G) and protease K
protection assays (Figure S4H) revealed a native pool of IL-1R2
in the cytosol without internal membrane disruption, as evi-
denced by a lack of calreticulin in cytosolic fractions. Finally,
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Figure 6. Caspase-1 Cleavage of IL-1R2
Restores Necrotic Cell-Induced IL-1a-
Dependent Inflammation
(A) Immunoblot for IL-1a in necrotic lysates from
LPS- and ATP-treated macrophages ± calpeptin
(during lysis) or ± caspase inhibitor Z-VAD (during
LPS and ATP treatment).
(B) IL-2 concentrations in conditioned media of
EL4 cells incubated with necrotic lysates from
control or LPS- and ATP-treated macrophages ±
a and/or b pAb, or ± Z-VAD (during LPS and ATP
treatment). Data represent mean ± SEM;
*p < 0.00004, **p% 0.02, nR 3.
(C and D) Immunoblot for IL-1R2 cleavage after
incubation with active caspase-1 ± Z-YVAD (C) or
a panel of active caspases (D).
(E) Edman degradation of cleaved IL-1R2 detected
two sequences (italic underlined) corresponding to
processing at two tetrapeptide sites (large bold).
(F) Immunoblot for cleaved IL-1R2 after mutation
of both caspase-1 sites.
(G) IL-2 concentrations in conditioned media of
EL4 cells incubated with IL-1a, and IL-1R2 ±
caspase-1 cleavage. Data represent mean ± SD;
*p = 0.009, n = 3.
(H) IL-1a concentration in conditioned media of
activated THP-1 cells transfected with caspase
site mutant IL-1R2, or as indicated. Data repre-
sentative of mean ± SD from n = 2.
See also Figure S5.
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IL-1R2 Controls IL-1a Activity Postnecrosisexpression of exogenous soluble IL-1R2 in VSMCs prevented
p33 cleavage (Figure 5G). Together these results demonstrate
that a cytosolic complex of p33 and IL-1R2 exists in many cell
types. During necrosis this prevents calpain cleavage of p33 to
the fully active p17 form, which reduces IL-1a-dependent
responses.
Caspase-1 Specifically Cleaves IL-1R2, which Restores
IL-1a-Dependent Inflammation Postnecrosis
Macrophages are suggested to be the sensors of necrotic-
derived DAMPs, which then release IL-1a to drive sterile inflam-
mation (Chen et al., 2007; Kono et al., 2010). However, our
current data indicate that macrophage IL-1a is bound to IL-
1R2, and therefore is nonfunctional. Because recent work
demonstrates that IL-1a secretion requires inflammasome acti-
vation (Fettelschoss et al., 2011), we investigated whether this
could overcome IL-1R2 blockade. Necrotic lysates made from
LPS and ATP-stimulated macrophages displayed processing
of p33, which could be prevented by the caspase inhibitor
Z-VAD-fmk or calpeptin (Figure 6A). Furthermore, after LPS
and ATP treatment, macrophage necrotic lysates induced IL-2
release from EL4 cells, which was blocked with Z-VAD-fmk orImmunity 38, 285–295,IL-1a- and IL-1b-neutralizing antibodies
(Figure 6B). IL-1R2 contains many pre-
dicted caspase sites (Figure S5A) and
cell-free cleavage resulted in caspase-1-
specific processing (Figure 6C). IL-1R2
could be cleaved by inflammatory
caspase-1 and caspase-5, but not by
caspase-4 or the apoptotic caspase-3(Figure 6D). To confirm the cleavage site, we mutated the P1
position Asp to Ala, resulting in a nonconsensus sequence for
caspases. Individual mutation of all sites that could give the
correct sized products did not prevent IL-1R2 processing (data
not shown). However, Edman degradation of the C-terminal
IL-1R2 fragment sequenced two products at equal abundance
corresponding to cleavage at two separate Asp residues 12
amino acids apart (Figure 6E), and subsequent mutation of
both these sites prevented cleavage (Figure 6F). The crystal
structure of IL-1R2 complexed to IL-1 (Wang et al., 2010) re-
vealed that cleavage at these sites would remove the D1
domain vital for binding. Indeed, antagonistic activity toward
IL-1a was lost upon processing (Figure 6G), whereas sham
cleavage reactions neither promoted nor inhibited IL-2 release
(Figure S5B), confirming that cleaved IL-1R2 cannot bind IL-
1a. Finally, caspase-1 cleavage of IL-1R2 appears to be a pre-
requisite for physiological IL-1a secretion, as indicated by the
fact that expression of the noncleavable IL-1R2 mutant reduced
IL-1a release (Figure 6H). Therefore, after exposure to stimuli
that activate inflammasomes, intracellular IL-1R2 is cleaved by
caspase-1, causing it to dissociate from IL-1a. Subsequently,
during necrosis calpain can now cleave IL-1a to the fully activeFebruary 21, 2013 ª2013 Elsevier Inc. 291
Immunity
IL-1R2 Controls IL-1a Activity Postnecrosisform, which allows the generation of robust IL-1a-dependent
responses.
DISCUSSION
Although an immune response to necrosis may resolve the orig-
inal pathology and initiate repair, recruited leukocytes can
damage the surrounding tissue. This sterile inflammatory
response can also lead to unwanted activation of adaptive
immunity. Many human diseases are driven by activation
of these pathways, including ischemia-reperfusion injury,
Alzheimer’s disease, atherosclerosis, and toxic insults to liver
and lung (Chen and Nun˜ez, 2010; Kono and Rock, 2008; Stewart
et al., 2010). Therefore, tight regulation of both release and
activity of DAMPs is critical for host defense.
The current understanding is that p33 is fully active and there-
fore requires only cell lysis to signal after necrosis. In contrast,
we find that activity is kept under tight control at multiple levels
in a cell type-dependent and conditional manner. Blocking
calpain processing of endogenous p33 during necrosis signifi-
cantly decreases activity, and comparison of recombinant
proteins demonstrates up to 50-fold increased activity of p17
compared to p33. This difference occurs at the receptor, with
a 50-fold greater affinity of p17 for IL-1R1. IL-1a cleavage
and activity after necrosis is cell type dependent because of
expression of a cytosolic IL-1R2, which binds and protects
IL-1a from cleavage and prevents IL-1a activity. IL-1R2 also pro-
tected IL-1a from granzyme B, chymase, and elastase cleavage,
suggesting that the primary control over IL-1a activity postnec-
rosis is by IL-1R2 binding. Lastly, active caspase-1 specifically
cleaves IL-1R2, causing dissociation from IL-1a, calpain pro-
cessing, and complete restoration of IL-1a activity after necrosis
or during regulated secretion.
DAMPs need to be retained on apoptosis, released on
necrosis, and able to activate the immune system. IL-1a is
near universally expressed (Dinarello, 2009), lacks a signal
peptide, is rarely extracellular under normal physiology, and
also associates with chromatin during apoptosis, resulting in
retention (Cohen et al., 2010). Other identified DAMPS include
heat shock proteins, uric acid, HMGB1, ATP, and dsDNA
(Kono and Rock, 2008). These DAMPs utilize specific cognate
receptors, such as RAGE, or pattern recognition receptors,
such as TLRs, which have a limited expression pattern that
restricts cell types able to respond. In contrast, IL-1R1 is widely
expressed throughout many lineages (Dinarello, 2009), enabling
IL-1a to act as a ‘‘universal’’ DAMP. Although this may provide
more efficient detection of necrosis, it could predispose the
immune system to overreact, perhaps explaining the extensive
control over IL-1a activity via release, IL-1R2 binding, and
calpain cleavage. This cell type and conditional dependency
for IL-1a activity after necrosis perhaps suggests an immune
advantage in allowing only some cell types to utilize IL-1a as a
DAMP.Previous studies concluded that IL-1a is only a secondary
signaling molecule released by macrophages during sterile
inflammation (Chen et al., 2007; Kono et al., 2010). However,
this finding might have occurred due to the use of necrotic cell
types that express IL-1R2 and therefore cannot cleave and utilize
IL-1a (Y.Z., M.H., and M.C.H.C.; data not shown). Indeed,
whereas control necrotic lysates induce an equivalent peritonitis292 Immunity 38, 285–295, February 21, 2013 ª2013 Elsevier Inc.in both wild-type and Il1r1/mice (representing the net effect of
all other DAMPS, independent of IL-1), necrotic cells without
IL-1R2 induced a 3-fold greater response, which was all IL-1
dependent. This key observation implies that without IL-1R2
expression, the single most powerful DAMP within necrotic
cells is IL-1a.
Our studies also identify multiple mechanisms that could give
a tissue- and cell type-dependent response to necrosis. Given
that p33 has some activity, dependent on its concentration
and sensitivity of the responding cells, extensive necrosis in an
IL-1R1-rich tissue (e.g., liver) could activate immunity regardless
of IL-1a cleavage. Conversely, minimal necrosis in an IL-1R1-low
tissue (e.g., kidney) that cannot cleave p33 may not respond
to IL-1a at all. If necrosis occurs with a stimulus that activates
caspase-1 (e.g., infection), IL-1R2 blockade is abrogated and
cleaved fully active p17 can signal to any IL-1R1-expressing
cell. Necrosis of cells that can cleave IL-1a within IL-1R1-dense
tissues would give extensive immune activation (e.g., vascular
tissue). Where the amount of IL-1R2, IL-1R1, and necrosis
preclude IL-1a activity, the response to necrosis could be
deferred to other DAMPs and specialist immune cells, perhaps
giving more control over reactions. Additionally, activation of
IL-1a during necrosis could act as a ‘‘tipping point’’ that drives
an inflammatory response toward adaptive immunity. Indeed,
this is the case in graft-versus-host disease, where injured
endothelial cell-derived IL-1a induces intimal T cell recruitment
and IL-17 production, driving human artery allograft rejection
(Rao et al., 2007, 2008).
Necrosis is induced bymany stimuli including physical trauma,
chemical stress, and bacterial toxins and is characterized by
loss of plasma membrane integrity (Kono and Rock, 2008).
Calpains are activated by Ca2+ entry after loss of membrane
integrity (Wang, 2000), and in VSMCs p33 cleavage occurs
immediately upon necrosis. Granzyme B is proposed to activate
IL-1a extracellularly (Afonina et al., 2011); but given its ineffi-
ciency to process IL-1a relative to calpain (Afonina et al.,
2011), cleavage within the necrotic body by calpain pro-
bably predominates when IL-1R2 is absent. IL-1a and IL-1b
arose from ancient gene duplications (Dinarello, 2009) but have
diverged molecularly. IL-1a is a DAMP that is activated by
a protease intrinsically linked to necrosis, whereas IL-1b is acti-
vated in response to PAMPs by a protease family intrinsically
linked to apoptosis and inflammation. However, these current
data indicate that in many cells IL-1a function requires both
calpain and caspase-1. Secretion of IL-1a from macrophages
(Fettelschoss et al., 2011) or dendritic cells (DCs) (Gross et al.,
2012) requires inflammasome activation, but given that IL-1a is
not a caspase substrate, this has been puzzling (Keller et al.,
2008). We suggest that IL-1R2 is the likely target of caspase-1
during physiological IL-1a release. Indeed, expression of an
uncleavable IL-1R2 mutant reduces IL-1a release, whereas
Casp1/ mice have long been known to be deficient in IL-1a
secretion (Kuida et al., 1995; Li et al., 1995).
An important finding of this work is that IL-1R2 binds p33 in
the cytosol. Although the previously described splice variant of
IL-1R2 (Liu et al., 1996) loses the transmembrane domain, it still
codes for a signal peptide and should be secreted. Despite this,
our data show that a large pool of IL-R2 exists in the cytosol. One
explanation for this is that the IL-1R2 signal peptide is short
Immunity
IL-1R2 Controls IL-1a Activity Postnecrosis(13 amino acids) and is predicted to be relatively weak (Signal P;
Y-max = 0.316) compared to other secreted proteins (e.g., IL-8;
Y-max = 0.790), and many proteins with signal peptides can
be found in the cytosol (Davis et al., 2006). Indeed, multiple
factors determine how much of a signal peptide-containing
protein ends up nontargeted, including the signal peptide and
flanking amino acid sequences and cell type and growth
condition effects (Levine et al., 2005). Clearly further work is
needed to elucidate the specific form of IL-1R2 that binds p33,
the mechanisms that generate it, and how this is controlled.
Cell type-specific effects of IL-1R2 expression may occur in
a number of diseases. Induction of antitumor immunity in vivo
is dependent upon the mode of cell death, whereby necrosis
is more immunogenic than apoptosis (Melcher et al., 1998)
and local IL-1 activity (Ghiringhelli et al., 2009; Michaud
et al., 2011). Necrosis can induce maturation of DCs and expres-
sion of costimulatory molecules and can stimulate T cells
(Basu et al., 2000; Sauter et al., 2000)—all processes critical
for antitumor immunity and all known activities of IL-1. Indeed,
differences are reported between the necrotic cell type and
ability to induce DC maturation (Sauter et al., 2000), perhaps
reflecting IL-1R2 expression and thus ability of necrotic cell-
derived IL-1a to modulate antigen-presenting cell function.
Intriguingly, IL-1R2 is upregulated in some tumors including
pancreatic ductal adenocarcinoma (Ru¨ckert et al., 2010) and
ovarian cancer, where it provides a powerful distinction between
primary and recurrent tumors (Laios et al., 2008). Finally, athero-
sclerosis is highly dependent on IL-1 (Chamberlain et al., 2009;
Chi et al., 2004; Duewell et al., 2010), although recent work casts
doubt on IL-1b’s role (Menu et al., 2011), suggesting that IL-1a
could be the major ligand affecting atherosclerotic plaques.
Indeed, necrotic VSMC-released IL-1a is a potent inducer of
local vessel inflammation in vivo (Clarke et al., 2010), and given
that VSMCs express high amounts of IL-1a and IL-1R1 but little
IL-1R2, their death is highly inflammatory.
In summary, in addition to acting as a decoy receptor, IL-1R2
also plays a hitherto unreported role that fundamentally controls
IL-1a activity postnecrosis. Cells expressing intracellular IL-1R2
release little active IL-1a after necrosis without prior activation of
caspase-1, which processes IL-1R2. In contrast, necrotic cells
devoid of IL-1R2 are inherently powerful inducers of sterile
inflammation able to fully activate IL-1a upon calpain cleavage.
Thus, changes in intracellular IL-1R2 expression may underlie
and modulate many chronic inflammatory diseases or other
pathologies involving cellular necrosis.
EXPERIMENTAL PROCEDURES
All materials are from Sigma-Aldrich unless otherwise stated.
Cell Culture
VSMCs,EL4,HEK, andHeLacellswerecultured inDMEMandJurkat andTHP-1
cells in RPMI 1640, all supplemented with penicillin, streptomycin, L-glutamine,
and 10% FCS. Human monocyte-derived macrophages were differentiated as
described previously (Brown et al., 2000). Cells were treated as indicated with
Calpeptin (30 mM), Lactacystin (10 mM; both Biomol), IL-1a pAb (1 mg/ml),
IL-1a and IL-1b (all PeproTech), IL-1RA (Amgen), IL-1R2 (250 ng; R&D),
Z-YVAD, Z-VAD-fmk (both 10 mm; Bachem), LPS (1 mg/ml), EGTA (5 mM), and
BB-94 (1 mg/ml; Tocris). Cells in serum-free (SF) DMEMwere disrupted by freeze
thaw in liquid N2, clarified, and stored at 80C. Cells were also made necrotic
by incubationwith 7-BIO (25mM;Enzo) or digitonin (0.1%) (data not shown) or byovernight hypoxic exposure. To activate inflammasomes, cellswere treatedwith
LPS (1 mg/ml; 4 hr), followed by ATP (5 mM) or Nigericin (20 mM) for 30 min.
Calpain activity was determined with Calpain-Glo (Promega). VSMCs, HEK,
and THP-1 cells were transfected with pcDNA3 (Invitrogen) with nucleofection
(Amaxa) or FugeneHD (Promega).Protein Expression and Purification
Human p33 (1-271) or p17 (119-271) was cloned into pET15b (Novagen) or
pGEX-4T-3 (GE). Human IL-1R2 (1-296) was cloned into pGEX-4T-3. For His
purification, IPTG-induced cultures were lysed in BugBuster (Novagen) with
benzonase, lysozyme, and protease inhibitors (10 min, RT). Urea (6 M) was
added and incubated (10 min) before clarification and purification on a Ni2+
column. Columns were washed (40 mM imidazole) and eluted (250 mM imid-
azole). Concentrated protein (Vivaspin) was dialyzed against decreasing urea
(4 M, 2 M, 0 M) in 10 mM Tris (pH 8.0), 50 mM NaCl. For GST purification,
IPTG-induced cultures were lysed in 50 mM Na2HPO4 (pH 7.5), 150 mM
NaCl, 1 mM DTT, 1 mM EDTA, with benzonase, lysozyme, and protease inhib-
itors (30 min, RT), clarified, applied to glutathione agarose (QIAGEN), washed,
eluted (50 mM reduced glutathione), concentrated, and dialyzed against
10 mM Tris (pH 8.0), 50 mM NaCl. GST tag was removed with biotinylated
thrombin (Novagen). Protein concentration was determined (660 nm; Thermo
Scientific), checked by Coomassie staining, and if necessary adjusted and
rechecked. Proteins were stored in 10% glycerol (80C).Protease Cleavage
His- or GST-p33 was incubated in 10 mM Tris (pH 7.5), 150 mM NaCl, 1 mM
DTT, 2 mM CaCl2, with calpain (Calbiochem) ± calpeptin or IL-1R2 (RT).
IL-1R2 was incubated with active caspase-1, caspase-3, caspase-4, or
caspase-5 (Promokine) in 50 mMHEPES (pH 7.2), 50 mMNaCl, 0.1%CHAPS,
10 mM EDTA, 5% glycerol, and 10 mM DTT (37C). Jurkat lysates were
also incubated with granzyme B (100 nM; Cambridge Bioscience), chymase,
or elastase (100 nM; both Enzo).Cytokine Release Assay
VSMCs were plated, adhered overnight, and incubated in SF DMEM (24 hr).
Fresh SF DMEM and treatments were added and incubated (6 hr). EL4 cells
were washed and plated in SF DMEM with treatments and incubated (24 hr).
17.5 3 103 necrotic VSMCs or macrophages or 5.25 3 104 necrotic Jurkat
or HeLa cells were used per 500 ml. Supernatants were clarified and cytokines
assayed by ELISA (PeproTech) or Cytomix (eBioscience).Immunoblotting, Edman Degradation, and Co-IP
Whole cell or necrotic lysates from 1 3 105 VSMCs or macrophages, or 3 3 105
Jurkat, HeLa, or T cells were loaded per lane. Antibodies used were IL-1a
(PeproTech), His (GE), a-spectrin (Millipore), b-actin (Sigma), calreticulin (Cell
Signaling), HDAC1 (Santa Cruz), and IL-1R2 (R&D). Caspase-1-cleaved IL-1R2
was separated, electroblotted to PVDF, and stained and bands were excised
for Edman degradation (ABI Procise 494HT). For co-IP, transfected HEK cells
were incubated on ice (50 mM Tris [pH 8], 150 mM NaCl, 1% Triton X-100,
protease inhibitors), freeze thawed, clarified, and incubated with 2 mg of anti-His
or anti-GST (GE) (16 hr, 4C). Immunocomplexeswere precipitatedwithmagnetic
protein-G beads (Dynal) and beads washed before elution with Laemmli buffer.RT-PCR
RNA was extracted with TRI reagent, DNase treated (Ambion), and reverse
transcribed (Promega) before PCR with the following primers: IL-1R1, AGGA
GACGGAGGACTTGTGT and GCGTCATAGGTCTTTCCATC; total IL-1R2,
CATTACAAGCGGGAGTTCAG and TAGTGCAGACGTAGGTGCCA; soluble
IL-1R2, TGGCACCTACGTCTGCACTA and TGTCTCCAAAAGGAAGAGCGA;
GAPDH, TGTTGCCATCAATGACCCCTT and CTCCACGACTGACTCAGCG.siRNA Silencing
IL-1R2 silencing was performed with SMARTpool siRNA and controls
(Dharmacon). In brief, HeLa cells were transfected with 20 nM of siRNA via
HiPerFect (QIAGEN), retransfected after 48 hr, and harvested 48 hr later.Immunity 38, 285–295, February 21, 2013 ª2013 Elsevier Inc. 293
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For IL-1R2, cells were fixed in 2% formaldehyde and permeabilized with 0.5%
NP-40. For IL-1R2 and p33, cells were fixed in 2% formaldehyde, washed,
and fixed with methanol. All were blocked in 1% BSA, incubated with IL-1R2
mAb (R&D) and anti-N-terminal IL-1a (Aviva Systems Biology), washed,
incubated with Alexa Fluor antibodies (Molecular Probes), washed, and
imaged on a BX51 (Olympus) or a TCS SP2 AOBS (Leica) microscope. PLA
assays with the primary antibodies as above were conducted according
to the manufacturer (Olink). For flow cytometry, cells were fixed in 2%
formaldehyde, washed, blocked in 1% BSA and 0.05% sodium azide, stained
with anti-IL-1R2, washed, stained with secondary antibodies, washed, and
analyzed on a C6 flow cytometer (Accuri). Intracellular staining steps had
0.5% saponin present.
Animal Protocols
Experiments were conducted under UK Home Office licensing. Mice were in-
jected intraperitoneally with saline, 0.29 fmol/g body weight of p17 or p33, or
8.33 104 necrotic HeLa cells. After 6 hr, the peritoneal cavity was lavaged with
5 ml of PBS. GR-1+ cells were counted by FACS after anti-GR-1-FITC staining
(Biolegend).
Statistics
Parametric tests were employed for analysis of continuous ELISA and
peritonitis data, conducted with a one-way, two-tailed ANOVA (Excel).SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at http://dx.doi.org/
10.1016/j.immuni.2013.01.008.
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Inventory of Supplemental Information  
 
 
Figure S1, related to Figure 1 – Assessment of IL-1α activity in membrane 
fractions of necrotic cells, and cells made necrotic by hypoxia; Western blot 
demonstrating cleavage of p33 to p17 IL-1α in the presence of calpeptin at 
37°C.  
 
Figure S2, related to Figure 3 – Dose response curve confirming GST has no 
effect on p33 IL-1α activity. 
 
Figure S3, related to Figure 4 – Western blots showing lack of IL-1α 
processing and IL-1R2 expression in primary T-cells and macrophages; 
Calpain activity in necrotic lysates; IL-1α processing in Jurkat lysates treated 
with an excess of IL-1RA or inflammatory proteases; dose response of IL-
1R2-mediated p33 IL-1α protection and antagonism; proximity ligation assays 
showing in situ binding.  
 
Figure S4, related to Figure 5 – Western blots showing lack of IL-1α 
processing in HeLa necrotic lysates, and Jurkat and primary T-cell and 
macrophage lysates treated with a metalloprotease inhibitor; 
Immunofluorescence showing intracellular IL-1R2 in HeLa cells and in other 
cell-types by FACs; Co-localization of native p33 IL-1α/IL-1R2 by 
epifluorescence and confocal microscopy; HeLa subcellular fractionation and 
protease K protection assays showing p33 IL-1α/IL-1R2 to be a cytosolic 
complex. 
 
Figure S5, related to Figure 6 – Sequence data showing predicted caspase 
cleavage sites; Histogram showing no effect of sham caspase cleavage 
reactions on EL4 cell response to IL-1α.    
 
 
 
Supplemental Experimental Procedures 
 
 
 
 
 
 
Figure S1, related to Figure 1: Necrosis-induced sterile inflammation is 
cell-type specific. (A,B) IL-2 concentrations in conditioned media of EL4 
cells incubated with soluble, membrane or whole fractions of necrotic lysates 
(A), or hypoxia-induced necrotic lysates (B), ± IL-1α neutralizing antibody (α 
pAb). Necrotic lysates were normalized to the level of necrosis by PI staining. 
Data representative of mean±SD from n=2. (C) Western blot for IL-1α in 
necrotic VSMC lysates after prolonged incubation at 37°C with calpeptin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2, related to Figure 3: Cytokine response to p33 IL-1α is not 
affected by a GST fusion tag.  p33 IL-1α had the GST fusion tag specifically 
cleaved off or was subjected to a ‘sham cleavage’, and was tested for ability 
to induce IL-2 from EL4 cells. Data represent mean ±SEM; p = NS; n = 3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3, related to Figure 4: Intracellular IL-1R2 protects IL-1α from 
calpain processing. (A) Western blot for IL-1α in whole cell (WC) or necrotic 
lysates (NL) of Jurkats and primary human T-cells. (B) Enzymatic assay for 
calpain activity within necrotic lysates from Jurkats, primary human 
macrophages and VSMCs. Data representative of n=3. (C-E) Western blot for 
IL-1α in Jurkat necrotic lysates following incubation with purified calpain, 
excess IL-1RA or calpeptin (C), IL-1R2 in whole cell or necrotic lysates from 
primary human macrophages and T-cells (D), IL-1α (30ng) processing after 
incubation with increasing amounts of IL-1R2 (E). (F) p33-induced (6.25ng/ml) 
IL-6 release in HeLa cells is dose-dependently antagonized by IL-1R2. (G) 
Proximity ligation assay, with antibodies as indicated, shows p33/IL-1R2 
association in situ in HeLa cells. (H) IL-1α in Jurkat necrotic lysates ± addition 
of proteases as indicated. 
 
 
 
 
 
 
Figure S4, related to Figure 5: IL-1R2 silencing enables calpain cleavage 
of IL-1α and restores inflammatory response to necrotic cells. (A,B) 
Western blot for IL-1α in necrotic HeLa lysates (A), or whole cell (WC) or 
necrotic lysates (NL) from Jurkat cells, and primary human T-cells and 
macrophages treated with the metalloprotease inhibitor BB-94 (B). (C,D) 
Immunofluorescence reveals IL-1R2 to be intracellular by microscopy in HeLa 
cells (C), or by FACs in multiple cell types (D). MFI=mean fluorescence 
intensity. (E,F) Dual immunolabeling of IL-1R2 and p33 IL-1α shows 
intracellular colocalization by fluorescent (E) and confocal (F) microscopy. 
MIP=maximum intensity projection. Scale bars = 25µm. (G,H) Western blot for 
IL-1α, IL-1R2, calreticulin and HDAC1 in HeLa lysates after subcellular 
fractionation (G), or after a protease K protection assay (H). C = cytosolic, M = 
membrane, sN = soluble nuclear, CHR = chromatin associated, INSL = 
insoluble pellet. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S5, related to Figure 6: Caspase-1 specifically cleaves IL-1R2 
which restores IL-1α-dependent inflammation post-necrosis. (A) The 
human IL-1R2 protein was analysed for caspase cleavage sites with the 
Cascleave (Red), Pripper (Green), and CASVM (Yellow) algorithms. (B) IL-2 
concentrations in conditioned media of EL4 cells incubated alone or with IL-
1α, ± sham caspase-1 cleavage reactions (+Sham). Data represents mean ± 
SD; p = NS, n = 2. 
 
 
 
 
 
 
Supplemental Experimental Procedures 
 
All materials from Sigma-Aldrich unless otherwise stated. 
 
Cell culture 
Human aortic VSMCs were isolated from patients with local ethics committee 
approval. VSMCs, EL4, HEK and HeLa cells were cultured in DMEM and Jurkat, 
and THP-1 cells in RPMI 1640, all supplemented with 10 U/ml penicillin, 10 mg/ml 
streptomycin, 5 mg/ml L-glutamine and 10% FCS. VSMCs, HEK, and HeLa cells 
were cultured to ~80% confluence before passaging. EL-4, Jurkat and THP-1 cells 
were maintained at 4-10x105 cells/ml. Human monocyte-derived macrophages were 
differentiated as described previously(Brown et al., 2000). Cells were treated as 
indicated with; Calpeptin (30µM), Lactacystin (10µM; both Biomol), IL-1α pAb 
(1µg/ml), IL-1α/β (1nM; all PeproTech), IL-1RA (Amgen), IL-1R2 (250ng; R&D), Z-
YVAD, Z-VAD-fmk (both 10µm; Bachem), LPS (1µg/ml), EGTA (5mM), BB-94 
(1µg/ml; Tocris). Cells in serum-free DMEM were disrupted by 3 rounds of 
freeze/thaw in liquid nitrogen in <1ml, clarified (13,000g, 5 mins) and stored at -80°C 
until use. Cells were also made necrotic by incubation with 7-Bromoindirubin-3'-
oxime (25µM; Enzo), pore formation with digitonin (0.1%)(not shown), or overnight 
hypoxic exposure. To activate inflammasomes, cells were treated with LPS (1µg/ml) 
for 4 h, followed by ATP (5mM) or Nigericin (20µM) for 30 mins. Calpain enzyme 
activity was determined using Calpain-Glo according to the manufacturer’s 
instructions (Promega). VSMCs and HEK/THP-1 cells were transfected with 
pcDNA3 (Invitrogen) using nucleofection (Amaxa) or FugeneHD (Promega), 
respectively, following the manufacturer’s protocols. 
Protein expression and purification 
Human IL-1α was cloned into pET15b and pET30a (Novagen) for His-tagging, or 
pGEX-4T-3 (GE) for GST-tagging, at residues 1-271 for p33 IL-1α or 119-271 for 
p17 IL-1α(Kobayashi et al., 1990). Soluble human IL-1R2 (1-296) was cloned into 
pGEX-4T-3. For His purification, log-phase bacterial cultures were induced with 
IPTG (1mM) for 3h at 37°C, pelleted, and lysed in BugBuster (Novagen) with 
benzonase (100u/ml), lysozyme (100 U/ml) and protease inhibitors (10mins, RT). 
Urea to 6 M was added and incubated (10 mins), before clarification and purification 
on a Ni2+ column. Briefly, supernatant was adjusted to pH 7.5, applied to the column, 
washed with 40 mM imidazole, and eluted with 250 mM imidazole. Following 
concentration (Vivaspin) protein was dialyzed against decreasing concentrations of 
urea (4 M, 2 M) in 10 mM Tris pH 8.0, 50 mM NaCl, at 4°C for 3 h each, and 
overnight (0 M). For GST purification, cultures were induced with IPTG (1 mM) for 
4h at RT, pelleted, and lysed in 50 mM Na2HPO4 pH 7.5, 150 mM NaCl, 1 mM DTT, 
1 mM EDTA, with benzonase (100 U/ml), lysozyme (100 U/ml), protease inhibitors 
at RT for 30mins, clarified and applied to glutathione agarose (Qiagen), washed, 
eluted with 50 mM reduced glutathione, concentrated and dialyzed against 10 mM 
Tris pH 8.0, 50 mM NaCl, at 4°C overnight. The GST tag was removed with 
biotinylated thrombin (Novagen). Protein concentration was determined with a Pierce 
660 protein assay (Thermo Scientific), checked for concentration and purity by 
Coomassie staining, and if necessary adjusted and rechecked. Proteins were stored in 
10% glycerol at -80°C. 
 
 
 
Protease cleavage 
His- or GST-p33 IL-1α (20ng - 2µg) was incubated in 10 mM Tris pH 7.5, 150 mM 
NaCl, 1 mM DTT, 2 mM CaCl2 with purified human erythrocyte calpain (0.5-30 U; 
Calbiochem) in a final volume of 30 µl ± calpeptin (30 µM) or IL-1R2 (250ng) for 30 
mins at RT. ‘Calpain sham’ reactions were assembled with calpain but without p33 
IL-1α. IL-1R2 (250ng – 2µg; R&D) was incubated with active caspase-1, 3, 4, 5 (1-10 
U; Promokine) in 50 mM HEPES pH 7.2, 50 mM NaCl, 0.1% CHAPS, 10 mM 
EDTA, 5% Glycerol, and 10 mM DTT for 2 – 16 h at 37°C. Cleaved IL-1R2 was 
dialyzed against DMEM before cell treatment. Jurkat necrotic lysates were also 
incubated with granzyme B (100 nM; Cambridge Bioscience), chymase or elastase 
(100 nM; both Enzo). 
 
Cytokine release assay 
VSMCs were plated at 1.5x104/well in 24-well plates, allowed to adhere overnight 
and incubated in serum free (S/F) DMEM for ~24 h. Fresh S/F DMEM was added to a 
final volume of 500 µl, including treatments and incubated for 6 h. EL4 cells were 
washed and plated at 1x105/well in S/F DMEM to a final volume of 500 µl including 
treatments and incubated for 24 h. The equivalent of 17.5x103 necrotic VSMCs or 
macrophages, or 5.25x104 necrotic Jurkat or HeLa cells were used per 500µl in 24-
well plates. For IL-1R2 antagonism, 5x103 HeLa cells were plated per well of a 96-
well plate, adhered overnight and treated with a sub-saturating concentration of p33 
(6.25ng/ml) ± IL-1R2 (0-50 µg/ml) in 100µl for 8 h. Supernatants were clarified by 
centrifugation and cytokine level assayed by ELISA (IL-6, MCP-1, IL-1α; 
PeproTech) or Cytomix (IL-2; eBioscience). 
 
Western blotting, Edman degradation and Co-IP 
Whole cell (directly lysed in Laemmli buffer) or necrotic lysates from 1x105 VSMCs 
or macrophages, or 3x105 Jurkat, HeLa, or primary T-cells were loaded per lane, 
which gave equivalent loading. Antibodies used were: anti-IL-1α (1:500; PeproTech), 
anti-His (1:12000; GE), anti-α-spectrin (1:1000; Millipore), anti-β-actin (1:100,000; 
Sigma), anti-calreticulin (1:1000; Cell Signalling), anti-HDAC1 (1:200; Santa Cruz) 
and anti-IL-1R2 (1:250; R&D). ~10 pmol of caspase-1 cleaved c-terminal IL-1R2 was 
separated on a gradient gel, electroblotted to PVDF, Coomassie stained and bands 
excised for Edman degradation (ABI Procise 494HT). For Co-IP, 4 x 106 HEK cells, 
transfected as indicated with p33 IL-1α-GST or IL-1R2-HIS, were incubated on ice 
for 10 mins (50mM Tris pH 8, 150mM NaCl, 1% Triton X-100, protease inhibitor 
cocktail), freeze/thawed 3x, clarified (13,000 g, 15 mins), and incubated with 2µg of 
anti-His or 2µg of anti-GST (GE) antibody overnight at 4°C. Immunocomplexes were 
precipitated with magnetic protein-G beads (Dynal), supernatants recovered, and 
beads washed 3x (PBS) before elution with Laemmli buffer. Half the Co-IP was 
loaded, whilst ~1/50th of the supernatant was loaded. 
 
Subceullular Fractionation  
HeLa cells were fractionated using the subcellular protein fractionation kit (Pierce) 
according to the manufacturer’s instructions. Sequential fractions equivalent to 
1.33x105 HeLa cells were loaded per lane. Staining for the ER protein calreticulin and 
soluble nuclear protein HDAC1 verified integrity of the extracts.   
 
 
 
Protease K protection assay  
Cytosolic HeLa cell extracts, made using the cytosol extraction buffer from the 
subcellular protein fractionation kit, were left untreated or treated with Triton X-100 
(1%), Protease K (250µg/ml), or both, in an ice bath (30 mins). Protease inhibitor 
cocktail and PMSF (1mM) was added, followed by immediate boiling in Laemmli 
buffer.  
 
RT-PCR 
RNA was extracted using TRI-reagent, DNAse treated (Ambion) and reverse 
transcribed (Promega) before PCR using the following primers: IL-1R1: 
AGGAGACGGAGGACTTGTGT & GCGTCATAGGTCTTTCCATC. Total IL-1R2: 
CATTACAAGCGGGAGTTCAG & TAGTGCAGACGTAGGTGCCA. Soluble IL-
1R2: TGGCACCTACGTCTGCACTA & TGTCTCCAAAAGGAAGAGCGA. 
GAPDH: TGTTGCCATCAATGACCCCTT & CTCCACGACTGACTCAGCG. 
 
siRNA knockdown 
IL-1R2 knockdown was performed using SMARTpool siRNA and controls according 
to the manufacturer’s instructions (Dharmacon). Briefly, HeLa cells were transfected 
with 20nM of siRNA using HiPerFect (Qiagen), re-transfected after 48 h, and 
harvested 48 h later. 
 
Immunofluorescence 
For IL-1R2 cells were fixed in 2% formaldehyde (15 mins, RT)  permeabilized with 
0.5% NP-40 (2 mins, RT). For IL-1R2/p33 cells were fixed in 2% formaldehyde, 
washed (PBS/0.05% Tween), and fixed on ice with ice cold methanol (10 mins). All 
were blocked in 1% BSA, incubated overnight at 4°C with anti-IL-1R2 mAb (1:40; 
R&D), anti-N-terminal IL-1α pAb (1:100; Aviva Systems Biology), or isotype 
controls, washed, incubated with Alexa Fluor anti-rabbit 488 or anti-mouse 568 
(1:500; Molecular Probes) for 1 h at RT, and washed before imaging on a BX51 
(Olympus) or a TCS SP2 AOBS (Leica) microscope. Proximity ligation assays were 
performed as above, but with substitution of 2ry antibodies for the Duolink probes, 
and then conducted according to the manufacturer’s protocol (Olink). For flow 
cytometry cells were fixed in 2% formaldehyde (10 mins, RT), washed, blocked in 
1% BSA (1 h, RT), stained with anti-IL-1R2 mAb (1:40) or anti-mouse IL-1R2 for 
EL4 cells (1:40, R&D),  washed, stained with Alexa Fluor anti-mouse 488 (1:500) or 
anti-goat FITC for EL4 (1:160), washed and analysed on a C6 (Accuri). For 
intracellular staining all steps, except fixation, had 0.5% saponin present. MFIs 
reported have surface or intracellular control values subtracted from the specific MFI. 
For intracellular-specific MFI the surface-specific value was subtracted. 
 
Animal Protocols 
Animal experiments were performed under UK Home Office licensing. Mice were 
injected intraperitoneally with saline or 0.29 fmol/g body weight of p17 or p33 IL-1α, 
or 8.3x104 necrotic HeLa cells. After 6 h, the peritoneal cavity was lavaged with 5ml 
of PBS. GR-1 +ve cells were enumerated by FACS following anti-GR-1-FITC 
staining (1:200; Biolegend). 
 
Statistics 
Parametric tests were employed for analysis of continuous ELISA and peritonitis data, 
which was conducted using a one-way, two-tailed ANOVA (Excel). 
